Managing Cancer Metabolically Part 3: Misinformation, GKI & the Future of Metabolic Oncology
Talking Cancer with Professor Thomas Seyfried
In Part 3 of this ongoing conversation, Dr. Donese Worden joins Professor Thomas Seyfried to discuss one of the greatest challenges facing modern cancer care—not just the science itself, but how scientific evidence is translated into clinical practice.
This discussion explores misinformation in oncology, the growing role of metabolic biomarkers such as the Glucose Ketone Index (GKI), and how education through the M.O.R.E. Alliance (Metabolic Oncology Research & Education Alliance) may help bridge the gap between research and patient care.
Related Episodes:
Misinformation and Scientific Literacy
Dr. Worden and Professor Seyfried discuss why misinformation spreads so easily within healthcare and why improving scientific literacy is essential for both clinicians and patients. They examine how individuals can better evaluate evidence, ask informed questions, and avoid oversimplified narratives surrounding cancer treatment.
The Glucose Ketone Index (GKI)
A major focus of this episode is the Glucose Ketone Index (GKI), a quantitative biomarker used in ketogenic metabolic therapy. The discussion explores how GKI can help guide metabolic interventions, why personalization matters, and the challenges of implementing ketogenic strategies effectively.
Food as Medicine and Metabolic Therapy
The conversation explores the growing "Food as Medicine" movement and the role nutrition may play in supporting metabolic health. Dr. Worden discusses how metabolic strategies are designed to complement—not replace—conventional medical care while emphasizing individualized treatment plans.
The Future of Metabolic Oncology
Dr. Worden and Professor Seyfried also discuss the mission of the M.O.R.E. Alliance, an organization focused on advancing research, education, clinician training, and patient access to evidence-based metabolic oncology.
They explore future goals including case registries, clinical research, physician education, and ultimately bringing metabolic oncology into mainstream medical education.
In This Interview You'll Learn
- Why misinformation continues to influence cancer care
- How the Glucose Ketone Index (GKI) is used in metabolic oncology
- The importance of personalized ketogenic metabolic therapy
- How stress influences metabolic health and cancer management
- The role of the M.O.R.E. Alliance in advancing metabolic oncology education
- Why translating research into patient care remains one of medicine's greatest challenges
Watch the full interview above to hear Dr. Donese Worden and Professor Thomas Seyfried discuss the future of metabolic oncology, patient empowerment, and the scientific principles shaping a new era of cancer care.
